Concerns about anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration treatment / 中华眼底病杂志

The introduction of anti-vascular endothelial growth factor (VEGF) therapy represents a landmark in the management of wet age-related macular degeneration (AMD).However,as a new therapy,several problems such as durability of the therapeutic effects,medication side effects,and medication selection have emerged.We should make appoint of improving the therapeutic effect and safety by realizing the limitation of the therapy,monitoring the clinical potential adverse reactions of anti-VEGF agents,and recommending individualized treatment.

Pay attention to the potential risks of anti-vascular endothelial growth factor therapy for neovascular disease / 中华眼底病杂志

Anti-vascular dndothelial growth factor (VEGF) drugs have open up a new treatment channel for ocular neovascular diseases.A lots of clinical data has proved that anti VEGF drugs are effective and safe.But we should also notice that long-term and excessive usage of anti-VEGF drugs brings some new problems and complications,and even affect the normal ocular physiological process of the angiogenesis and retinal blood flow.So,it is necessary to pay attention to the problems and potential risks of excessive usage of anti VEGF therapies for ocular neovascular disease.